Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis

Adrian R Martineau,1,2* David A Jolliffe,1 Lauren Greenberg,1 John F Aloia,3 Peter Bergman,4 Gal Dubnov-Raz,5 Susanna Esposito,6 Davaasambuu Ganmaa,7 Adit A Ginde,8 Emma C Goodall,9 Cameron C Grant,10 Wim Janssens,11 Megan E Jensen,12 Conor P Kerley,13 Ilkka Laaksi,14 Semira Manaseki-Holland,15 David Mauger,16 David R Murdoch,17 Rachel Neale,18 Judy R Rees,19 Steve Simpson Jr,20 Iwona Stelmach,21 Geeta Trilok Kumar,22 Mitsuyoshi Urashima,23 Carlos A Camargo Jr,24 Christopher J Griffiths1,2,25 and Richard L Hooper1

1Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
2Asthma UK Centre for Applied Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
3Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY, USA
4Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
5Department of Exercise, Lifestyle and Nutrition Clinic, Edmond and Lily Safra Children’s Hospital, Tel Hashomer, Israel
6Pediatric Highly Intensive Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
7Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
8Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
9Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
10Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
11Universitaire ziekenhuizen Leuven, Leuven, Belgium
12Centre for Asthma and Respiratory Diseases, University of Newcastle, Newcastle, NSW, Australia
13Dublin City University, Dublin, Ireland
Declared competing interests of authors: Susanna Esposito reports grants and personal fees from GlaxoSmithKline (GSK) plc (GSK House, Middlesex, UK), grants and personal fees from Pfizer Inc. (New York, NY, USA), grants and personal fees from Sanofi Pasteur MSD [Sanofi Pasteur (Lyon France) and Merck Sharp & Dohme Corp. (MSD, Kenilworth, NJ, USA)], grants from DuPage Medical Group (DMG, Downers Grove, IL, USA), personal fees from Valeas S.p.A. (Milan, Italy), and grants and personal fees from Vifor Pharma (Bern, Switzerland), outside the submitted work. Emma Goodall reports personal fees from GSK outside the submitted work. Wim Janssens reports grants from Instituut voor Innovatie door Wetenschap en Technologie (IWT)–Vlaanderen and from Laboratoires SMB (Brussels, Belgium) during the conduct of the study. David Mauger reports funding from the National Heart, Lung, and Blood Institute, MA, USA. Rachel Neale reports grants from the National Institutes of Health and the Medical Research Council during the conduct of the study. Judy R Rees reports that a use patent is held by Dartmouth College and Dr John A Baron for calcium as a chemopreventive agent. Dr Baron is not an author on this paper but is the principal investigator of the parent study from which the study by Rees (Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, Sandler RS, et al. Vitamin D₃ supplementation and upper respiratory tract infections in a randomized, controlled trial. Clin Infect Dis 2013;57:1384–92) was conducted. The patent was previously licensed by Pfizer (with royalties), but has not been licensed for about 5 years. Judy R Rees is not involved in the patent and the patent does not involve vitamin D.
Scientific summary

Vitamin D supplementation to prevent acute respiratory infections
Health Technology Assessment 2019; Vol. 23: No. 2
DOI: 10.3310/hta23020

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

**Background**

Acute respiratory infections (ARIs) are a major cause of global morbidity and mortality. Observational studies report consistent independent associations between low serum concentrations of 25-hydroxyvitamin D \([25(\text{OH})\text{D}]\), the major circulating vitamin D metabolite, and susceptibility to ARI. The observation that \(25(\text{OH})\text{D}\) supports induction of antimicrobial peptides in response to both viral and bacterial stimuli suggests a potential mechanism by which vitamin D-inducible protection against these outcomes may be mediated. Vitamin D metabolites have also been reported to induce other innate antimicrobial effector mechanisms, including autophagy and synthesis of reactive nitrogen intermediates and reactive oxygen intermediates.

These epidemiological and in vitro data have prompted numerous randomised controlled trials (RCTs) to determine whether or not vitamin D supplementation can decrease the risk of ARI. A total of five aggregate data meta-analyses incorporating data from up to 15 primary trials have been conducted to date, of which two report statistically significant protective effects and three report no statistically significant effects. All but one of these aggregate data meta-analyses reported significant heterogeneity of effect between primary trials. Such heterogeneity of effect may have arisen as a result of intertrial variation in participant characteristics and in dosing regimens, either of which may modify the effects of vitamin D supplementation on immunity to respiratory pathogens. Subgroup analyses within primary trials of vitamin D supplementation for diverse indications show that participants with lower baseline vitamin D status may derive greater clinical benefit from supplementation than those with higher baseline status. Administration of large boluses of vitamin D has been associated with reduced efficacy for non-classical effects of vitamin D and, in some cases, increased risk of adverse outcomes. Although study-level factors are amenable to exploration via aggregate data meta-analysis of published data, potential effect modifiers operating at an individual level, such as baseline vitamin D status, can only be explored using individual participant data (IPD) meta-analysis. This is because subgroups are not consistently disaggregated in trial reports, and consistent adjustments for potential confounders cannot be applied. In order to determine the overall effect of vitamin D supplementation on the risk of ARI and to identify factors that might modify the effects of this intervention on the risk of ARI, we undertook a meta-analysis of IPD from RCTs that had investigated these outcomes.

**Main objectives**

1. To determine the overall effect of vitamin D supplementation on the risk of ARI and serious adverse events.
2. To determine whether or not the following factors modify the effect of vitamin D supplementation on the risk of ARI:
   i. baseline vitamin D status
   ii. vitamin D dosing regimen
   iii. size of vitamin D dose
   iv. age
   v. body mass index
   vi. presence versus absence of respiratory comorbidity [e.g. asthma, chronic obstructive pulmonary disease (COPD)]
   vii. influenza vaccination status.
Methods

Data sources
Two investigators searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials Number (ISRCTN) registry for eligible studies from database inception until December 2015.

Study selection (eligibility criteria)
Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D₃ or vitamin D₂ of any duration were eligible for inclusion in the ARI analysis if they had been approved by a Research Ethics Committee and if data on incidence of ARI were collected prospectively and prespecified as an efficacy outcome. Studies reporting results of long-term follow-up of primary RCTs were excluded.

Data management
Individual participant data were requested from the principal investigator for each eligible trial, and the terms of collaboration were specified in a data transfer agreement, signed by representatives of the data provider and the recipient (Queen Mary University of London). Data relating to study characteristics were extracted for the following variables: setting, eligibility criteria, details of intervention and control regimens, study duration and case definitions for ARI. IPD were extracted for the following variables, when available: baseline data were requested for age, sex, cluster identification (cluster randomised trials only), influenza vaccination status, history of asthma, history of COPD, weight, height (adults and children able to stand) or length (infants), serum 25(OH)D concentration, study allocation (vitamin D vs. placebo) and details of any stratification or minimisation variables. Follow-up data were requested for the total number of ARIs, upper respiratory infections (URIs) and lower respiratory infections (LRIs) experienced during the trial, time from first dose of study medication to first ARI/URI/LRI if applicable, total number of courses of antibiotics taken for ARI during the trial, total number of days off work or school as a result of ARI symptoms during the trial, serum 25(OH)D concentration at final follow-up, duration of follow-up, number and nature of serious adverse events, number of adverse reactions (incident hypercalcaemia or renal stones) and end-trial status (completed vs. withdrew vs. lost to follow-up vs. died).

Data were de-identified at source prior to transfer via e-mail. On receipt, three investigators assessed data integrity by performing internal consistency checks and by attempting to replicate the results of the analysis for ARI incidence when this was published in the trial report. Study authors were contacted to provide missing data and to resolve queries arising from these integrity checks. Once queries had been resolved, clean data were uploaded to the main study database.

Assessment of validity
The Cochrane Collaboration Risk of Bias tool was used to assess the following variables: sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; completeness of outcome data; evidence of selective outcome reporting; and other potential threats to validity.

Data synthesis
Initially, all studies were reanalysed separately; the original authors were asked to confirm the accuracy of this reanalysis when it had been performed previously, and any discrepancies were resolved. Then we performed both one-step and two-step IPD meta-analysis using a random-effects model adjusted for age, sex and study duration to obtain the pooled intervention effect on (1) the proportion of participants experiencing at least one ARI, (2) ARI rate and (3) time to first ARI with a 95% confidence interval (CI). The number needed to treat (NNT) for an additional beneficial outcome was calculated in which meta-analysis of dichotomous outcomes revealed a statistically significant beneficial effect of allocation to vitamin D compared with placebo.

In order to explore the causes of heterogeneity and identify factors modifying the effects of vitamin D supplementation on ARI risk, we also performed prespecified subgroup analyses by extending the one-step meta-analysis framework to include treatment–covariate interaction terms. Subgroups were defined
according to baseline vitamin D status (serum 25(OH)D concentration of < 25 nmol/l vs. ≥ 25 nmol/l), vitamin D dosing regimen (daily or weekly administration without bolus dosing vs. administration of a regimen including at least one bolus dose of ≥ 30,000 IU (international units) of vitamin D), dose size (daily equivalent < 800 IU vs. 800–1999 IU vs. ≥ 2000 IU), age (≤ 1 year vs. 1.1–15.9 years vs. 16–65 years vs. > 65 years), body mass index (< 25 kg/m² vs. ≥ 25 kg/m²) and presence versus absence of asthma, COPD and previous influenza vaccination. Interaction analyses were adjusted for potential confounders (age, sex and study duration) in order to ensure that reported subgroup effects were independent. In order to minimise the chance of type I error arising from multiple analyses, significance was inferred only when p-values for treatment–covariate interaction terms were < 0.05.

Results

We identified 25 RCTs (total 11,321 participants, aged from 0 to 95 years) that were eligible for the ARI analysis. These trials were conducted in 15 different countries on four continents and enrolled participants of both sexes from birth to 95 years of age. The mean baseline 25(OH)D concentration ranged from 18.9 to 88.9 nmol/l. All studies administered oral vitamin D₃ to participants in the intervention arm: this was given as monthly to once every 3 months bolus doses in seven studies, as weekly doses in three studies, as a daily dose in 12 studies and as a combination of bolus and daily doses in three studies. Study duration ranged from 7 weeks to 1.5 years. Incidence of ARI was a primary or coprimary outcome for 14 studies and a secondary outcome for 11 studies.

Individual participant data were obtained for 10,933 out of 11,321 (96.6%) participants in these studies. In the one-step IPD meta-analysis, vitamin D supplementation resulted in a statistically significant reduction in the proportion of participants experiencing at least one ARI [adjusted Odds Ratio (aOR) 0.88, 95% CI 0.81 to 0.96; p = 0.003, p for heterogeneity < 0.001; 10,933 participants in 25 studies]. The number needed to benefit was 33 (95% CI 20 to 101). Statistically significant protective effects of vitamin D were also seen for one-step analyses of ARI rate [adjusted incidence rate ratio (aIRR) 0.96, 95% CI 0.92 to 0.997; p = 0.04; p for heterogeneity < 0.001; 10,703 participants in 25 studies] but not for analysis of time to first ARI [adjusted hazard ratio (aHR) 0.95, 95% CI 0.89 to 1.01; p = 0.09; p for heterogeneity < 0.001; 9108 participants in 18 studies]. Two-step analyses showed consistent effects for the proportion of participants experiencing at least one ARI (aOR 0.80, 95% CI 0.69 to 0.93; p = 0.004; p for heterogeneity = 0.001; 10,899 participants in 24 studies), ARI rate (aIRR 0.91, 95% CI 0.84 to 0.98; p = 0.018; p for heterogeneity < 0.001; 10,703 participants in 25 studies) and time to first ARI (aHR 0.92, 95% CI 0.85 to 1.00; p = 0.051; p for heterogeneity = 0.14; 9108 participants in 18 studies). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83). This evidence was assessed as being of high quality.

Subgroup analyses revealed a strong protective effect of vitamin D supplementation among individuals with baseline circulating 25(OH)D concentration of < 25 nmol/l (aOR 0.58, 95% CI 0.40 to 0.82; NNT 8, 95% CI 5 to 21; 538 participants in 14 studies; within subgroup, p = 0.002), and no statistically significant effect among those with baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.89, 95% CI 0.77 to 1.04; 3634 participants in 19 studies; within subgroup, p = 0.15; for interaction, p = 0.01). Stronger protective effects of vitamin D against ARIs were also seen in trials in which vitamin D was administered using a daily or weekly regimen without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91; NNT 20, 95% CI 13 to 43; 5133 participants in 15 studies; within subgroup, p < 0.001); no such protective effect was seen among participants in trials in which at least one bolus dose of vitamin D was administered (aOR 0.97, 95% CI 0.86 to 1.10; 5800 participants in 10 studies; within subgroup, p = 0.67; p for interaction = 0.05). For both of these subgroup analyses, broadly consistent effects were observed for event rate analysis and survival analysis. The p-values for interaction were > 0.05 for all other potential effect modifiers investigated.
We then proceeded to stratify the subgroup analyses according to dosing frequency, in order to provide a cleaner look at results of subgroup analyses under the assumption that administration of bolus doses was ineffective. The results of this exploratory analysis suggested that daily or weekly administration of vitamin D induced an even greater degree of protection against ARI among participants with baseline circulating 25(OH)D concentrations of < 25 nmol/l than in the unstratified analysis (aOR 0.30, 95% CI 0.17 to 0.53; NNT 4, 95% CI 3 to 7; 234 participants in six studies; within subgroup, $p < 0.001$). Moreover, administration of daily or weekly vitamin D also protected against ARI among participants with higher baseline 25(OH)D concentrations (aOR 0.75, 95% CI 0.60 to 0.95; NNT 15, 95% CI 9 to 86; 1603 participants in six studies; within subgroup, $p = 0.02$). The $p$-value for interaction for this subgroup analysis was 0.006, indicating that protective effects of daily or weekly vitamin D supplementation were significantly greater in the subgroup of participants with profound vitamin D deficiency. No other statistically significant interaction was seen; notably, bolus dose vitamin D supplementation did not offer any protection against ARI even when administered to those with circulating 25(OH)D concentrations of < 25 nmol/l (aOR 0.82, 95% CI 0.51 to 1.33; 304 participants in eight studies; within subgroup, $p = 0.43$).

Limitations

Our power to detect effects of vitamin D supplementation was limited for some subgroups [e.g. individuals with baseline 25(OH)D concentration of < 25 nmol/l receiving bolus-dosing regimens]. Null and borderline significant results for analyses of these outcomes may have arisen as a consequence of type II error. Data relating to adherence to study medication were not available for all subjects. However, the inclusion of non-adherent participants would bias results of our intention-to-treat analysis towards the null; thus, we conclude that effects of vitamin D in those who are fully adherent to supplementation will be no less than those reported for the study population overall. Finally, we caution that study definitions of ARI were diverse, and virological, microbiological and/or radiological confirmation was obtained for a minority of events. ARI is often a clinical diagnosis in practice, however, and as all studies were double-blind and placebo-controlled, differences in incidence of events between study arms cannot be attributed to observation bias.

Conclusions

Implications for health care

Our synthesis of the current evidence suggests that vitamin D supplementation can prevent ARIs, broadly defined. We identified that the greatest potential benefit is for those individuals who are very deficient in vitamin D. Those receiving daily or weekly supplementation without additional bolus doses also experienced particular benefit. Our results add to the body of evidence supporting the introduction of public health measures, such as food fortification, to improve vitamin D status in settings in which profound vitamin D deficiency is common.

Recommendations for research

1. Incorporation of additional IPD from ongoing trials in the field has the potential to increase statistical power for subgroup analyses; this IPD meta-analysis should therefore be updated when a significant new body of data has accumulated.
2. Given the major impact of ARIs on economic productivity and health-care use, our findings are likely to influence the economic case for the introduction of vitamin D fortification of foods in the UK. Economic models of the cost-effectiveness of vitamin D fortification in the UK should therefore be updated to take account of the previously unappreciated protective effects of vitamin D against ARIs.
Study registration

This study is registered as PROSPERO CRD42014013953.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

**HTA programme**

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: [http://www.nets.nihr.ac.uk/programmes/hta](http://www.nets.nihr.ac.uk/programmes/hta)

**This report**

The research reported in this issue of the journal was funded by the HTA programme as project number 13/03/25. The contractual start date was in October 2014. The draft report began editorial review in January 2017 and was accepted for publication in October 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Martineau et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk